Soteria Biotherapeutics

Soteria Biotherapeutics is a biotechnology company developing cancer immunotherapies that is headquartered in San Francisco, California and was founded in 2018 by Alexander Martinko and Zachary Hill.

Soteria Biotherapeutics is developing t-cells that are conditioned to engage antibodies to treat solid tumor cancers. Their platform T-LITETM, offers small molecule-dependent activation of bispecific antibody therapies. The platform is designed to enable treatments through pulsatile activity, and reduce side effects.

The platform incorporates a small molecule-controlled switch to carry out its use and T-cell cytotoxic activity. The platform creates the activity of immunomodulatory therapeutics such as bi-specific T-Cell engagers, and CAR T-cells. Soteria Biotherapeutics offers services in order to develop their protein switches.